<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiоlоgy and infectious diseases. Сurrent items</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiоlоgy and infectious diseases. Сurrent items</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни. Актуальные вопросы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2226-6976</issn><issn publication-format="electronic">2414-9640</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">716196</article-id><article-id pub-id-type="doi">10.18565/epidem.2026.16.2.6-12</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Epidemic Situation</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Эпидемическая ситуация</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The significance of asymptomatic and mild forms of the disease in the development of the epidemic process of the novel coronavirus infection (COVID-19)</article-title><trans-title-group xml:lang="ru"><trans-title>Значение бессимптомных и легких форм заболевания в развитии эпидемического процесса новой коронавирусной инфекции (COVID-19)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4228-9044</contrib-id><name-alternatives><name xml:lang="en"><surname>Akimkin</surname><given-names>Vasily G.</given-names></name><name xml:lang="ru"><surname>Акимкин</surname><given-names>Василий Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Academician of Russian Academy of Sciences, MD, Professor, Director</p> <p> </p></bio><bio xml:lang="ru"><p>академик РАН, д.м.н., профессор, директор</p> <p> </p></bio><email>crie@pcr.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5456-7649</contrib-id><name-alternatives><name xml:lang="en"><surname>Esman</surname><given-names>Anna S.</given-names></name><name xml:lang="ru"><surname>Есьман</surname><given-names>Анна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Med. Sci., Head, Laboratory of Molecular Epidemiology and Immunology</p>
<p> </p></bio><bio xml:lang="ru"><p>к.м.н., заведующий лаборатории молекулярной эпидемиологии и иммунологии</p>
<p> </p></bio><email>esman@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3093-5731</contrib-id><name-alternatives><name xml:lang="en"><surname>Dubodelov</surname><given-names>Dmitriy V.</given-names></name><name xml:lang="ru"><surname>Дубоделов</surname><given-names>Дмитрий Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Med. Sci., Leading Research Scientist, Laboratory of Molecular Epidemiology and Immunology</p>
<p> </p></bio><bio xml:lang="ru"><p>к.м.н., ведущий научный сотрудник, лаборатории молекулярной эпидемиологии и иммунологии</p>
<p> </p></bio><email>dubodelov@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0121-521X</contrib-id><name-alternatives><name xml:lang="en"><surname>Gasanov</surname><given-names>Gasan A.</given-names></name><name xml:lang="ru"><surname>Гасанов</surname><given-names>Гасан Алиевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Med. Sci.,Research scientist, Laboratory of Molecular Epidemiology and Immunology</p>
<p> </p></bio><bio xml:lang="ru"><p>к.м.н., научный сотрудник лаборатории молекулярной эпидемиологии и иммунологии</p>
<p> </p></bio><email>gasanov@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7502-6473</contrib-id><name-alternatives><name xml:lang="en"><surname>Makhova</surname><given-names>Tamara I.</given-names></name><name xml:lang="ru"><surname>Махова</surname><given-names>Тамара Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Med. Sci., Senior Researcher, Laboratory of Molecular Diagnostics and Epidemiology of Reproductive Infections</p>
<p> </p></bio><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник лаборатории молекулярной диагностики и эпидемиологии инфекций органов репродукции</p>
<p> </p></bio><email>dolgova@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-3956-2148</contrib-id><name-alternatives><name xml:lang="en"><surname>Beregovykh</surname><given-names>Roman M.</given-names></name><name xml:lang="ru"><surname>Береговых</surname><given-names>Роман Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head, Product Analytics for Scientific Production, Center for Scientific and Marketing Communications</p>
<p> </p></bio><bio xml:lang="ru"><p>руководитель направления аналитики по продуктам научного производства, центр научных и маркетинговых коммуникаций</p>
<p> </p></bio><email>beregovykh@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-9950-2649</contrib-id><name-alternatives><name xml:lang="en"><surname>Monakhova</surname><given-names>Angelina A.</given-names></name><name xml:lang="ru"><surname>Монахова</surname><given-names>Ангелина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate</p>
<p> </p></bio><bio xml:lang="ru"><p>аспирант</p>
<p> </p></bio><email>monaxova.angelina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8557-6540</contrib-id><name-alternatives><name xml:lang="en"><surname>Sycheva</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Сычева</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Healthcare-associated Infections</p>
<p> </p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории инфекций, связанных с оказанием медицинской помощи</p>
<p> </p></bio><email>sycheva.n@cmd.su</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being</institution></aff><aff><institution xml:lang="ru">Центральный НИИ эпидемиологии Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2026</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>6</fpage><lpage>12</lpage><history><date date-type="received" iso-8601-date="2026-07-08"><day>08</day><month>07</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-07-08"><day>08</day><month>07</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО «Бионика Медиа»</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://journals.eco-vector.com/2226-6976/about/editorialPolicies#purchaseIssue</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/2226-6976/article/view/716196">https://journals.eco-vector.com/2226-6976/article/view/716196</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> Determination of the epidemiological significance of the proportion of asymptomatic and mild forms in the dynamics of the incidence rate and structure of the novel coronavirus infection (COVID-19) globally and in the Russian Federation (RF) for 2020–2022.</p> <p><bold>Materials and methods.</bold> Data from the online resource Our World in Data was used to analyze COVID-19 incidence in populations across different countries. Information on the level and dynamics of incidence in the Russian Federation and the distribution of cases by severity were obtained by analyzing Rospotrebnadzor’s statistical form No. 1035, “Monitoring the number of cases of coronavirus infection, including community-acquired pneumonia, and fatalities,” for 2020–2022.</p> <p><bold>Results. </bold>The overall proportion of asymptomatic and mild forms of the disease in 2020–2022 ranged from 51.5% to 80.6%, averaging 64.2 ± 10.6%.</p> <p><bold>Conclusion.</bold> The high proportion of asymptomatic and mild forms of COVID-19 demonstrates the extreme epidemiological importance of timely diagnosis of such cases to prevent the spread of the pathogen.</p> <p> </p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования.</bold> Определение эпидемиологической значимости доли бессимптомных и легких форм в динамике уровня и структуры заболеваемости новой коронавирусной инфекцией (COVID-19) в мире и в Российской Федерации (РФ) за 2020–2022 гг.</p> <p><bold>Материалы и методы. </bold>Для анализа заболеваемости COVID-19 населения разных стран мира использованы данные интернет-ресурса Our World in Data. Сведения об уровне и динамике заболеваемости населения РФ и распределении заболевших по степени тяжести получены при анализе статистической формы Роспотребнадзора №1035 «Мониторинг количества заболевших коронавирусной инфекцией, в том числе внебольничными пневмониями, и летальных исходов» за 2020–2022 гг.</p> <p><bold>Результаты. </bold>Суммарное значение доли бессимптомных и легких форм заболевания в 2020–2022 гг. колебалось от 51,5 до 80,6% и в среднем составило 64,2 ± 10,6%.</p> <p><bold>Заключение.</bold> Высокие доли бессимптомных и легких форм COVID-19 свидетельствуют о чрезвычайной эпидемиологической значимости своевременной диагностики таких случаев заболевания для профилактики распространения возбудителя.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>epidemiological surveillance</kwd><kwd>genomic epidemiological surveillance</kwd><kwd>SARS-CoV-2</kwd><kwd>asymptomatic forms</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>эпидемиологический надзор</kwd><kwd>геномный эпидемиологический надзор</kwd><kwd>SARS-CoV-2</kwd><kwd>бессимптомные формы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Maison D.P., Tasissa H., Deitchman A., Peluso M.J., Deng Y., de Miller W. et al. COVID-19 clinical presentation, management, and epidemiology: a concise compendium. Front. Public Health 2025; 13: 1498445. DOI: 10.3389/fpubh.2025.1498445</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Xu Y., Chen Y., Tang X. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. Glob. Health Med. 2020; 2(2): 66–72. DOI: 10.35772/ghm.2020.01015</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Акимкин В.Г., Дубоделов Д.В., Есьман А.С., Кузин С.Н., Углева С.В., Черкашина А.С. и др. Цифровые решения (VGARus, SOLAR, «EpidSmart － модуль COVID») в системе эпидемиологического надзора за новой коронавирусной инфекцией (COVID-19). Эпидемиол. инфекц. болезни. Актуал. вопр. 2025; 15(1): 43–50. [Akimkin V.G., Dubodelov D.V., Esman A.S., Kuzin S.N., Ugleva S.V., Cherkashina A.S. et al. Digital solutions (VGARus, SOLAR, «EpidSmart － COVID Module») in the system of epidemiological surveillance of the new coronavirus infection (COVID-19)]. Epidemiology and infectious diseases. Current items 2025; 15(1): 43–50. (In Russ.)]. DOI: 10.18565/epidem.2025.15.1.43-50</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Акимкин В.Г., Дубоделов Д.В., Есьман А.С., Береговых Р.М., Махова Т.И., Гасанов Г.А. и др. Эпидемиологическая и экономическая эффективность массового ПЦРобследования населения Российской Федерации в период эпидемии новой коронавирусной инфекции (COVID-19). Эпидемиология и Вакцинопрофилактика 2025; 24(6): 28–35. [Akimkin V.G., Dubodelov D.V., Esman A.S., Beregovykh R.M., Makhova T.I., Gasanov G.A. et al. Epidemiological and economic efficiency of mass PCR testing of the population in the Russian Federation during the COVID–19 epidemic. Epidemiology and Vaccinal Prevention 2025; 24(6): 28–-35 (In Russ.)]. DOI: 10.31631/2073-3046-2025-24-6-28-35</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Syangtan G., Bista S., Dawadi P., Rayamajhee B., Shrestha B.L., Tuladhar R. et al. Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis. Front. Public Health 2021; (8): 587374. DOI: 10.3389/fpubh.2020.587374</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ma Q., Liu J., Liu Q., Kang L., Liu R., Jing W. et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw. Open. 2021; 4(12): e2137257. DOI: 10.1001/jamanetworkopen.2021.37257</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Tan J., Ge Y., Martinez L., Sun J., Li Ch., Westbrook A. et al. Transmission roles of symptomatic and asymptomatic COVID-19 cases: a modelling study. Epidemiol. Infect. 2022; 150: e171. DOI: 10.1017/S0950268822001467</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Buitrago-Garcia D., Egli-Gany D., Counotte M.J., Hossmann S., Imeri H., Mert Ipekci A. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020; 17(9): e1003346. DOI: 10.1371/journal.pmed.1003346</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Акимкин В.Г., Семененко Т.А., Дубоделов Д.В., Хафизов К.Ф., Углева С.В. Теория саморегуляции паразитарных систем и COVID-19. Вестник Российской академии медицинских наук 2024; 79(1): 33–41. [Akimkin V.G., Semenenko T.A., Dubodelov D.V., Khafizov K.F., Ugleva S.V. The Theory of Self-Regulation of Parasitary Systems and COVID-19. Annals of the Russian academy of medical sciences 2024; 79(1): 33–41. (In Russ.)]. DOI: 10.15690/vramn11607</mixed-citation></ref></ref-list></back></article>
